Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates

Nerviano Medical Sciences Srl, a clinical-stage biotechnology company member of NMS Group Spa, the largest cancer research and development company in Italy, announced signing of a license agreement and right of option with Solve Therapeutics, Inc. to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.

NMS is focused on discovery and development of innovative therapies for the treatment of cancer based on proprietary kinase and ADC linker-payload platforms, with approved targeted drugs licensed to pharma companies and proprietary innovative small molecules undergoing clinical studies. The development program will leverage NMS’s proprietary innovative linker-payload platform technology and

SolveTx’s antibody-based oncology therapeutics technology. NMS’s linker-payload platform is carefully designed to generate more stable, efficacious, and safer ADCs to treat heterogenous and chemotherapy-resistant solid tumors. The licensed linker-payload includes optimized features; it can be readily conjugated to targeting antibodies, is highly active in preclinical in vitro and in vivo studies, shows bystander activity in heterogeneous tumors, promotes immune system recognition of tumor cells to induce immunogenic cell death, and demonstrates activity in chemotherapy-resistant and poorly proliferating tumors while maintaining a wide therapeutic index.

“We are excited to partner with SolveTx to extend our pipeline beyond our world-famous kinase platform and clinical assets to create

> estrusori > dosatori > componenti > trasporto pneumatico > sistemi completi